Back to today’s briefing

Story perspectives

Novo Nordisk Shares Jump on Semaglutide Heart Data

3/17/2025

25 5

Summary

Story summary

Novo Nordisk's shares surged over 3% on Monday, fueled by the exciting announcement of new data on semaglutide's heart risk reduction, set to be unveiled at the American College of Cardiology Scientific Session. However, the company faces challenges, with shares down 7% this year and a staggering 40% decline over the past 12 months.

1 of 1

Story summary

Novo Nordisk's shares surged over 3% on Monday, fueled by the exciting announcement of new data on semaglutide's heart risk reduction, set to be unveiled at the American College of Cardiology Scientific Session. However, the company faces challenges, with shares down 7% this year and a staggering 40% decline over the past 12 months.